Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients With Refractory Cancer Pain

NCT03362073 is registered in ClinicalTrials.gov with Pusan National University Yangsan Hospital as lead sponsor.

NCT NCT03362073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients With Refractory Cancer Pain
Lead sponsor
Pusan National University Yangsan Hospital
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2018
Completion date
January 31, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ketamine, refractory cancer pain